22nd Nov 2013 07:29
LONDON (Alliance News) - Sinclair IS Pharma PLC Friday said it has sold acne treatment Effederm, radiation dermatitis Xclair and dry mouth treatments SST and Salinum for a total of GBP1.1 million in cash, part of its strategy of focusing on a smaller number of treatment areas.
"These disposals continue the board's strategy of focusing group resource on a smaller number of key Dermatology brands with clear growth potential in Aesthetics, Wound Care, and Skin Care," the company said in a statement.
Effederm will be bought by France's Labaratoires Bailleul SA, and the others by Hexim Pharmaceuticals. Effedern has GBP0.3 million of revenues in the 12 months to end-June, which the rest had revenues of GBP0.2 million.
By Steve McGrath; [email protected]; @SteveMcGrath1
Copyright © 2013 Alliance News Limited. All Rights Reserved.
Related Shares:
Sinclair Pharma